Technology & Strategy
The Best Target & The Best Chemical
Various genetic and epigenetic changes occur before normal cells become metastatic cancer. As a result, cancer cells acquire cell growth, metastasis, angiogenesis, adsorption and invasion to the extracellular matrix, and secretion of inflammatory substances to change the tumor microenvironment to be suitable for the growth and survival of cancer cells. The refractory and recurrence of cancer cells to various existing anticancer therapies is due to the interaction between the cancer cells and the tumor microenvirotnment, or the presence and characteristics of cancer stem cells that may exist in the cancer cell population. Pharos iBio is the optimal target that can inhibit the signaling system and DNA replication mechanisms related to aggression, refractory or recurrence of cancer cells by using the self-established big data and AI-based new drug development platform “chemiverse”.

-
First
Signaling system in cancer cells and
Inhibition of DNA replication mechanism -
Second
Tumor Microenvironment and
Blocking interactions between cancer cellsCancer cell proliferation, angiogenesis and
metastasis, From the tumor microenvironment
that affects resistance Impeding signalingAs a secreted substance of cancer cells (growth
factor, cytokines, etc) Suppression of changes in
tumor/immune microenvironment caused by -
Third
Unlimited selfrenewal of cancer stem cells
and inhibition of apoptosis resistanceCancer stem cells are the cause of cancer
recurrence and resistance to anticancer drugsCan be caused by mutations and expression
changes It is a small group, and because of its
immortality and dedifferentiation characteristics,
Gained strong resistance to
The new drug development platform technology possessed by Pharos iBio is being used in the development of new drugs in the entire stage of “Discovery”, from the discovery of the active substance of the compound to the discovery of the active substance. In addition, by applying an algorithm that can expand the indications of candidate substances, we discover new indications for existing compounds and expand the excellent pipeline. In fact, Pharos iBio PHI-101 candidates are being developed by expanding three clinical pipelines based on damaged DNA repair mechanisms (DNA Damage Repair inhibitory mechanisms) through analysis of indications other than acute myelogenous leukemia through this strategy.
Chemiverse System
-
Drug DB
15,000 -
Chemical Library
200,000,000 -
BioActive Chemical Library
10,000,000 -
3D Protein structure DB
180,000 -
BioActivity Data
35,000,000
-
Structure-based
virtual search -
Deep Learning
Prediction Model -
Network-based
model -
Other models
-
New Hit
Compoud -
ADME
Prediction -
Toxicity
Prediction -
New Drug
Indication -
New Drug
Target -
Kinase
Profile
-
Data collection in the field of
new drug development -
Development of
predictive model based
on artificial intelligence -
Application of predictive
model for each stage of
new drug development
Pharos iBio introduces profiling technology using molecular biological diagnostic techniques to develop new drugs based on big data and artificial intelligence. Analyzing the diversity of patient responses to new drugs and discovering genetic and non-genetic biomarkers by analyzing differences between drug mechanisms and genome functions, and epigenetic differences according to different genetic and environmental factors and lifestyles for each patient So you can induce an optimized customized treatment.
Which
Drugs?Who
needs
treatmentWhat
does?
